Production, characterization, and testing of banked mammalian cell substrates used to produce biological products

In Vitro Cellular and Developmental Biology - Animal

Volumn 41, Issue 3-4, 2005, Pages 65-70

  Schiff, Leonard J ^a  

^a CHARLES RIVER LABORATORIES   (United States)

Author keywords

Biotechnology products; Cell banks

Indexed keywords

COMPLEMENTARY DNA; RECOMBINANT DNA; BIOLOGICAL PRODUCT;

ANIMAL CELL; BACTERIUM; BIOTECHNOLOGY; DNA SEQUENCE; FUNGUS; GENE EXPRESSION; GENETIC STABILITY; MAMMAL CELL; MICROBIAL CONTAMINATION; MYCOPLASMA; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; QUALITY CONTROL; RETROVIRUS; REVIEW; SAFETY; VIRUS; VIRUS DETECTION; ANIMAL; CELL CULTURE; CELL LINE; CULTURE MEDIUM; CULTURE TECHNIQUE; MAMMAL; METHODOLOGY; STANDARD;

ANIMALIA; FUNGI; MAMMALIA; MYCOPLASMATALES;

ANIMALS; BIOLOGICAL PRODUCTS; CELL CULTURE TECHNIQUES; CELL LINE; CELLS, CULTURED; CULTURE MEDIA; MAMMALS;

EID: 22344443894     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1290/0503024.1     Document Type: Review

References (23)

1. Beale, A. S. Choice of cell substrate for biological products. Adv. Exp. Med. Biol. 118:83-97; 1979.
2. Berthold, W.; Werz, W.; Walter, J. K. Relationship between nature and source of risk and process validation. In: Brown, F.; Lubiniecki, A. S., ed. Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev. Biol. Stand., vol. 88. Basel, Switzerland: Karger; 1995: 59-71.
3. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res. 104:255-262; 1977.
4. Code of Federal Regulations. Title 9, Parts 113.46, 113.47, 113.51. Subchapter E-viruses, senims, toxins, and analogous products; organisms and vectors. Washington, DC: U.S. Government Printing Office: 2004.
5. Code of Federal Regulations. Title 21, Part 210. Current good manufacturing practice in manufacturing, processing, packing, and holding of drugs, general. Washington. DC: US Government Printing Office; 2004.
6. Committee for Proprietary Medicinal Products, Ad Hoc Working Party on Biotechnology/Pharmacy, European Commission. Production and Quality Control of Monoclonal Antibodies (revision). Note for Guidance, 111/5271/94, 1995.
7. European Medicines Evaluation Agency [EMEA]. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products, CPMP/BWP/1793/02.
8. European Pharmacopoeia, Section 2.6.7, 2003.
9. Freshney, R. I., ed. Culture of animal cells: a manual of basic technique. 4th ed. New York: Wiley-Liss; 2000.
10. Hayflick, L. A brief history of cell substrates used for the preparation of human biologicals. In: Brown, F.; Lewis, A., Jr.; Peden, K.; Krause, P., ed. Evolving scientific and regulatory perspectives on cell substrates for vaccine development. Dev. Biol. Stand., vol. 106. Basel, Switzerland: Karger; 1999:5-24.
11. Hopps, H. E.; Petricciani, J. C., eds. Abnormal cells, new products and risks. Gaithersburg, MD: Tissue Culture Association; 1985.
12. Horaud, F. Viral safety of biological products and the concept of validation. In: Brown, F.; Lubiniecki, A. S., ed. Viral safety and evaluation of viral clearance from biopharmaceutical products. Dev. Biol. Stand., vol. 88. Basel, Switzerland: Karger; 1995:19-24.
13. ICH Q5A Guidance for Industry: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human and Animal Origin. FDA implementation: published in the federal register, vol. 63, no. 185, September 24, 1998, 51074-51084.
14. ICH Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. FDA implementation: published in the federal register, vol. 61, no. 37, February 23, 1996, 7006-7008.
15. ICH Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. FDA implementation: published in the federal register, vol. 63, no. 182, September 21, 1998, 50244-50249.
16. National Cancer Institute Monograph (USA), 29, 1968.
17. Olson, L. D.; Barile, M. F. Mycoplasma infection of cell cultures; isolation and detection. J. Tissue Cult. Methods 11:175-179; 1988.
18. Petricciani, J. C. Cell line issues: historical and future perspectives. In: Brown, F.; Esber, E. E.; Williams, M., ed. Continuous cell lines-an international workshop on current issues. Dev. Biol. Stand., vol. 76. Basel, Switzerland: Karger: 1991:5-11.
19. Petricciani, J. C.; Hopps, H. E.; Chapple, P. J., eds. Cell substrates. New York: Plenum; 1979.
20. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. CBER/FDA; 1993.
21. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. CBER/FDA: 1997.
22. Symposium on Diploid Cells, Minimum requirements of the establishment of a HDCS to be used for the production of human virus vaccines and minimum requirements for the production of human virus vaccines in HDCS. In: Proceedings of the symposium on the characterization and uses of human diploid cell strains. Opatija, Yugoslavia: Permanent Section of Microbiological Standardization; 1963. p. 709-715.
23. WHO. Requirements for continuous cell lines used for biological production. In: WHO Expert Committee on biological standardization. Geneva, Switzerland: World Health Organization, 1987, Annex 3 (WHO Technical Report Series No. 745).